GLP-1 Injectable Dropout Rates and the Compliance Crisis
Most patients quit GLP-1 injections within a year due to nausea during dose escalation.
Marcus Wexler
Staff Writer
Marcus Wexler
Marcus Wexler is a staff writer at Delivery Platform Review covering glp-1 therapeutics. Based in Mexico City, Marcus has written for Delivery Platform Review since 2017.
1 story · Mexico City